Iterum Therapeutics announces $5M registered direct offering of ordinary shares and pre-funded warrants

Iterum Therapeutics plc

Gross proceeds of $5.0M from sale of 5,555,556 shares/warrants at $0.90 each.
Net proceeds ~$4.2M after fees; H.C. Wainwright acting as placement agent.
Funding to support pre-commercialization of ORLYNVAH and strategic process, cash runway into 2026.
Offering expected to close April 30, 2025, subject to customary conditions.
Pre-funded warrants exercisable at $0.01 per share with 9.99% beneficial ownership cap.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.